Clinical Importance of Treating Iron Overload in Sickle Cell Disease

Clinical Trial ID NCT00981370

Rank	Title	Journal	Year	PubWeight™‹?›
1	A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.	Blood	2005	6.07
2	A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.	Br J Haematol	2007	1.77
3	Improvement of sickle cell anemia by iron-limited erythropoiesis.	Am J Hematol	1994	1.53
4	Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases.	Hemoglobin	2008	1.23
5	Arterial stiffness and endothelial function in patients with beta-thalassemia major.	Circulation	2002	1.10
6	Iron in sickle cell disease: a review why less is better.	Am J Hematol	2003	1.09
7	Cardiovascular autonomic dysfunction in sickle cell anemia: a possible risk factor for sudden death?	Clin Auton Res	1997	1.07
8	Abnormal cardiac autonomic control in sickle cell disease following transient hypoxia.	Conf Proc IEEE Eng Med Biol Soc	2008	0.81
9	Compartmentalization of iron in sickle cell anemia--an autopsy study.	Am J Clin Pathol	1985	0.76